Skip to content
buyWeak cluster of 2

Opaleye Management Inc. bought $32k of GRCE

owner at Grace Therapeutics, Inc.. 15,089 shares at an average of $2.10, traded Sep 21, 2026, filed Oct 1, 2026.

Conviction score
38
Value
$32k
15,089 shares
Holdings after
2,790,318
+1% from before
From 52-week low
+1%
low $2.07, close $2.10
From 52-week high
-59%
high $5.13, as of Sep 21, 2026

Score components

  • Role
    10% owner
    +12
  • Trade size
    $32k at market
    +5
  • Relative to holdings
    Under 1% of holdings (0.5%)
    -5
  • Price context
    1% above the 52-week low; 59% below the 52-week high
    +18
  • Cluster
    2 insiders buying within 14 days
    +8
  • Repeat buying
    2 buys in 90 days
    +5
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GRCEOct 9, 2026 · close 2.08
Since filing Oct 1, 2026: +2.0%SPY +1.9% · excess +0.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001493152-26-045347, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 21, 2026POpen-market purchase
Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P.
+9,771$2.10$21k2,785,00011 d ago
Sep 23, 2026POpen-market purchase
Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P.
+5,318$2.10$11k2,790,31811 d ago

Related signals

Other insiders at Grace Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
40Moderate
GRCEbuy
Grace Therapeutics, Inc.
Opaleye Management Inc.
owner
$124k
60,490 shares
+2%
25Weak
GRCEbuy
Grace Therapeutics, Inc.
Opaleye Management Inc.
owner
$16k
7,849 shares
+0%
38Weak
GRCEbuy 2
Grace Therapeutics, Inc.
Opaleye Management Inc.
owner
$32k
15,089 shares
+1%
73Notable
GRCEbuy 2
Grace Therapeutics, Inc.
Prashant Kohli
Chief Executive Officer
$214k
100,000 shares
+468%
33Weak
GRCEbuy 2
Grace Therapeutics, Inc.
Opaleye Management Inc.
owner
$32k
15,229 shares
+1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Opaleye Management Inc. bought $32k of GRCE | InsiderTell